伊立替康
医学
结直肠癌
奥沙利铂
肿瘤科
内科学
疾病
重症监护医学
癌症
作者
Éric Van Cutsem,Bernard Nordlinger,René Adam,Claus‐Henning Köhne,Carmelo Pozzo,Graeme Poston,Marc Ychou,Philippe Rougier
标识
DOI:10.1016/j.ejca.2006.04.012
摘要
Colorectal cancer (CRC) caused nearly 204,000 deaths in Europe in 2004. Despite recent advances in the treatment of advanced disease, which include the incorporation of two new cytotoxic agents irinotecan and oxaliplatin into first-line regimens, the concept of planned sequential therapy involving three active agents during the course of a patient's treatment and the integrated use of targeted monoclonal antibodies, the 5-year survival rates for patients with advanced CRC remain unacceptably low. For patients with colorectal liver metastases, liver resection offers the only potential for cure. This review, based on the outcomes of a meeting of European experts (surgeons and medical oncologists), considers the current treatment strategies available to patients with CRC liver metastases, the criteria for the selection of those patients most likely to benefit and suggests where future progress may occur.
科研通智能强力驱动
Strongly Powered by AbleSci AI